Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00567476 |
This study investigates asthma-related quality of life in Brazilian patients using omalizumab.
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: Omalizumab Drug: conventional therapy |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Open-Label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to Isolated Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing in the Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma |
Estimated Enrollment: | 123 |
Study Start Date: | November 2007 |
Estimated Study Completion Date: | February 2009 |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: Omalizumab
conventional therapy (inhaled corticosteroids and long acting beta agonist) and Omalizumab
|
2: Active Comparator |
Drug: conventional therapy
conventional therapy (inhaled corticosteroids and long acting beta agonist)
|
Ages Eligible for Study: | 12 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Novartis | 41 61 324 1111 |
Brazil | |
Novartis Investigator Site | Recruiting |
São Paulo, Brazil | |
Contact 41 61 324 1111 |
Study Chair: | Novartis Pharma | Novartis Pharma |
Responsible Party: | Novartis ( External affairs ) |
Study ID Numbers: | CIGE025ABR01 |
Study First Received: | December 4, 2007 |
Last Updated: | August 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00567476 |
Health Authority: | Brazil: Ministry of Health |
Asthma, anti-immunoglobulin E, omalizumab |
Antibodies Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases Hypersensitivity, Immediate |
Quality of Life Asthma Immunoglobulins Omalizumab Respiratory Hypersensitivity |
Respiratory System Agents Immune System Diseases Bronchial Diseases Therapeutic Uses |
Anti-Asthmatic Agents Anti-Allergic Agents Pharmacologic Actions |